Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions for challenging neurodegenerative, metabolic, and alcohol misuse disorders. The company’s strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across multiple stages of development while leveraging scientific research, intellectual property, and commercial relationships.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company also invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake (as of March 31, 2026) and royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The company was highlighted in a recent article discussing its diversified platform and strategic investments. The publication noted, “The company’s strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives.” To view the full article, visit https://ibn.fm/JtLc5.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. The company’s approach leverages scientific research, intellectual property, and commercial relationships as part of its broader business strategy. For the latest news and updates relating to QNTM, visit https://ibn.fm/QNTM.
The company’s diversified platform and strategic investments position it to address significant unmet medical needs while supporting multiple potential revenue streams. Quantum BioPharma continues to advance its clinical-stage therapeutics and consumer-focused wellness products, aiming to deliver long-term growth and value.
